AveXis (AVXS) Given New $112.00 Price Target at Bank of America

AveXis (NASDAQ:AVXS) had its price objective lowered by Bank of America from $115.00 to $112.00 in a report published on Friday, November 10th. The firm currently has a buy rating on the stock.

Several other research analysts also recently issued reports on the company. Royal Bank Of Canada upped their price objective on AveXis from $92.00 to $97.00 and gave the stock a sector perform rating in a report on Friday, November 10th. Chardan Capital reaffirmed a buy rating on shares of AveXis in a report on Thursday, November 2nd. Zacks Investment Research downgraded AveXis from a buy rating to a hold rating in a research note on Monday, October 30th. Canaccord Genuity assumed coverage on AveXis in a research note on Thursday, October 26th. They issued a hold rating and a $110.00 price target on the stock. Finally, BMO Capital Markets reissued an outperform rating and issued a $130.00 price target (up previously from $123.00) on shares of AveXis in a research note on Thursday, October 12th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $110.67.

AveXis (NASDAQ AVXS) traded down $1.07 during midday trading on Friday, reaching $93.85. The company had a trading volume of 228,300 shares, compared to its average volume of 428,303. AveXis has a 1-year low of $44.68 and a 1-year high of $108.27.

AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same period last year, the company posted ($0.87) earnings per share. analysts anticipate that AveXis will post -6.23 earnings per share for the current year.

In other AveXis news, insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $101.46, for a total transaction of $1,521,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $93.25, for a total transaction of $165,985.00. Following the sale, the vice president now owns 1,780 shares of the company’s stock, valued at $165,985. The disclosure for this sale can be found here. Insiders sold a total of 35,340 shares of company stock valued at $3,559,683 over the last quarter. 18.60% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of the business. Amalgamated Bank lifted its position in AveXis by 19.6% during the third quarter. Amalgamated Bank now owns 3,187 shares of the company’s stock worth $308,000 after acquiring an additional 523 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in AveXis by 2.9% during the second quarter. Parametric Portfolio Associates LLC now owns 20,943 shares of the company’s stock worth $1,721,000 after acquiring an additional 598 shares during the last quarter. American International Group Inc. lifted its position in AveXis by 26.7% during the first quarter. American International Group Inc. now owns 3,521 shares of the company’s stock worth $268,000 after acquiring an additional 742 shares during the last quarter. Seven Bridges Advisors LLC lifted its position in AveXis by 49.4% during the second quarter. Seven Bridges Advisors LLC now owns 2,557 shares of the company’s stock worth $210,000 after acquiring an additional 846 shares during the last quarter. Finally, Jennison Associates LLC raised its position in shares of AveXis by 0.5% in the second quarter. Jennison Associates LLC now owns 184,668 shares of the company’s stock valued at $15,172,000 after buying an additional 882 shares in the last quarter. Hedge funds and other institutional investors own 92.88% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/bank-of-america-corporation-lowers-avexis-inc-avxs-price-target-to-112-00/1775267.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.